Phosphorylation by glycogen synthase kinase-3 controls c-Myc proteolysis and subnuclear localization

被引:362
作者
Gregory, MA [1 ]
Qi, Y [1 ]
Hann, SR [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Cell & Dev Biol, Nashville, TN 37232 USA
关键词
D O I
10.1074/jbc.M310722200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The c-Myc protein is a transcription factor that is a central regulator of cell growth and proliferation. Thr-58 is a major phosphorylation site in c-Myc and is a mutational hotspot in Burkitt's and other aggressive human lymphomas, indicating that Thr-58 phosphorylation restricts the oncogenic potential of c-Myc. Mutation of Thr-58 is also associated with increased c-Myc protein stability. Here we show that inhibition of glycogen synthase kinase-3 (GSK-3) activity with lithium increases c-Myc stability and inhibits phosphorylation of c-Myc specifically at Thr-58 in vivo. Conversely, overexpression of GSK-3alpha or GSK-3beta enhances Thr-58 phosphorylation and ubiquitination of c-Myc. Together, these observations suggest that phosphorylation of Thr-58 mediated by GSK-3 facilitates c-Myc rapid proteolysis by the ubiquitin pathway. Furthermore, we demonstrate that GSK-3 binds c-Myc in vivo and in vitro and that GSK-3 colocalizes with c-Myc in the nucleus, strongly arguing that GSK-3 is the c-Myc Thr-58 kinase. We found that c-MycS, which lacks the N-terminal 100 amino acids of c-Myc, is unable to bind GSK-3; however, mutation of Ser-62, the priming phosphorylation site necessary for Thr-58 phosphorylation, does not disrupt GSK-3 binding. Finally, we show that Thr-58 phosphorylation alters the subnuclear localization of c-Myc, enhancing its localization to discrete nuclear bodies together with GSK-3.
引用
收藏
页码:51606 / 51612
页数:7
相关论文
共 48 条
  • [1] ALBERT T, 1994, ONCOGENE, V9, P759
  • [2] The amino-terminal phosphorylation sites of C-MYC are frequently mutated in Burkitt's lymphoma lines but not in mouse plasmacytomas and rat immunocytomas
    Axelson, H
    Henriksson, M
    Wang, Y
    Magnusson, KP
    Klein, G
    [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) : 2099 - 2104
  • [3] c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover
    Bahram, F
    von der Lehr, N
    Cetinkaya, C
    Larsson, LG
    [J]. BLOOD, 2000, 95 (06) : 2104 - 2110
  • [4] POINT MUTATIONS IN THE C-MYC TRANSACTIVATION DOMAIN ARE COMMON IN BURKITTS-LYMPHOMA AND MOUSE PLASMACYTOMAS
    BHATIA, K
    HUPPI, K
    SPANGLER, G
    SIWARSKI, D
    IYER, R
    MAGRATH, I
    [J]. NATURE GENETICS, 1993, 5 (01) : 56 - 61
  • [5] The c-myc transactivation domain is a direct modulator of apoptotic versus proliferative signals
    Chang, DW
    Claassen, GF
    Hann, SR
    Cole, MD
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (12) : 4309 - 4319
  • [6] Myc-mediated transformation: the repression connection
    Claassen, GF
    Hann, SR
    [J]. ONCOGENE, 1999, 18 (19) : 2925 - 2933
  • [7] CLARK HM, 1994, CANCER RES, V54, P3383
  • [8] Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: Transrepression correlates with acceleration of apoptosis
    Conzen, SD
    Gottlob, K
    Kandel, ES
    Khanduri, P
    Wagner, AJ
    O'Leary, M
    Hay, N
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (16) : 6008 - 6018
  • [9] Crystal structure of glycogen synthase kinase 3β:: Structural basis for phosphate-primed substrate specificity and autoinhibition
    Dajani, R
    Fraser, E
    Roe, SM
    Young, N
    Good, V
    Dale, TC
    Pearl, LH
    [J]. CELL, 2001, 105 (06) : 721 - 732
  • [10] Glycogen synthase kinase 3β regulates cyclin D1 proteolysis and subcellular localization
    Diehl, JA
    Cheng, MG
    Roussel, MF
    Sherr, CJ
    [J]. GENES & DEVELOPMENT, 1998, 12 (22) : 3499 - 3511